Alison Banham
Antibodies to shut off the blood supply
University of Oxford
Oxford
OX3 9DU
United Kingdom
Web: Lab website
Professor Alison Banham and her team at the University of Oxford are producing new biological cancer drugs called antibodies that target molecules found on the surface of cancer cells.
Antibodies are made naturally by the body, where they are used to kill invading bacteria or viruses, but they can also be made by researchers in the lab to target cancer cells.
Professor Banham is focusing on making antibodies that target a tumour’s blood supply, potentially starving the cancer cells of the oxygen and nutrients that they need to survive. Once Professor Banham and her team have made and tested antibodies that hit these targets in the lab, they will select the best ones for large-scale production and testing in clinical trials.
Treatment with monoclonal antibodies – such as rituximab (Mabthera or Rituxan), used to treat leukaemia and lymphoma - has improved the outlook for many patients with different types of cancer. Professor Banham’s work holds promise for developing powerful new therapies for cancer in the future.
Other research projects by Alison Banham
Clinical and Translational Research Committee Programme Grants
Funding period: 01 July 2009 to 30 June 2014
Publications
Aberrant expression of the neuronal transcription factor FOXP2 in neoplastic plasma cells
Br J Haematol.2010;149 :221-230
Defense of the clone: antibody 259D effectively labels human FOXP3 in a variety of applications
Blood.2008;111 :3897-3899






Read press release 